VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement

VERAXA Biotech has secured $27.5 million in senior secured note financing and a $50 million share purchase agreement with Lincoln Park Capital Fund to support its business combination with Voyager Acquisition Corp. and advance its pipeline of cancer therapies. VERAXA shareholders have approved the merger and issuance of new shares, with the combined company expected to list on NASDAQ under the ticker 'VRXA'.